Showing 6701-6710 of 8842 results for "".
- Upadacitinib Effective in Adolescents With AD Through 76 Weekshttps://practicaldermatology.com/news/upadacitinib-effective-adolescents-ad-through-76-weeks/2468724/Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib demonstrated a favorable benefit-risk profile, with sustained efficacy responses through 76 weeks, in a study published in JAMA Dermatology. “Upadacitinib in Adolescents With Moderate to Sev
- Study: Cutaneous Lupus Linked With Elevated Cardiovascular Disease Riskhttps://practicaldermatology.com/news/study-cutaneous-lupus-linked-elevated-cardiovascular-disease-risk/2468723/Patients with cutaneous lupus erythematosus (CLE) face an elevated risk of atherosclerotic cardiovascular disease (ASCVD), comparable to that seen in systemic lupus erythematosus (SLE), according to a new study. Authors of the retrospective cohort study analyzed health records of 8,138 pat
- Almirall Announces Scientific Research Hub at R&D Centerhttps://practicaldermatology.com/news/almirall-announces-scientific-research-hub-rd-center/2468710/Almirall announced the launch of “The Hive,” a novel scientific research hub located at its R&D center in Barcelona, Spain. According to a press release, the Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s
- Study Highlights Gaps in Fitzpatrick Skin Type Determinationhttps://practicaldermatology.com/news/study-highlights-gaps-fitzpatrick-skin-type-determination/2468709/New research published in The Journal of Clinical and Aesthetic Dermatology evaluated concordance between self-assessed and provider-determined Fitzpatrick skin types (FSTs). Study researchers conducted the analysis of 472 patients attending a dermatology practice and included dat
- Early-Onset AD Linked to Higher Rates of Atopic Marchhttps://practicaldermatology.com/news/early-onset-ad-linked-higher-rates-atopic-march/2468704/Early-onset atopic dermatitis (AD) is associated with higher rates of developing atopic march conditions compared to controls, according to new research in the Journal of the American Academy of Dermatology. “Particular attention should be paid towards risk factors and atopic marc
- Analysis: Dermoscopy Raises Diagnostic Odds for Melanoma Accuracyhttps://practicaldermatology.com/news/analysis-dermoscopy-raises-diagnostic-odds-melanoma-accuracy/2468666/Experienced dermatologists achieve significantly higher diagnostic accuracy for skin cancer than primary care physicians (PCPs), particularly when using dermoscopy, according to a new meta-analysis of 100 studies. The review, published in JAMA Dermatology, focused on diagnostic accuracy fo
- Study Links Skin Microbiota and AD Alleviation via Melatoninhttps://practicaldermatology.com/news/study-links-skin-microbiota-and-ad-alleviation-melatonin/2468664/A new study published in the Journal of Allergy and Clinical Immunology indicates melatonin has been shown to reduce atopic dermatitis (AD) symptoms by altering skin microbiota composition, with short-chain fatty acids (SCFAs) such as propionic acid playing a key role in this process. Alth
- Dupilumab Shows Long-Term Survival Rates in Treating Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/dupilumab-shows-long-term-survival-rates-treating-moderate-severe-atopic-dermatitis/2468646/A recent literature review of published studies suggested that dupilumab maintained survival rates of 80–90% at 1, 2, and 3 years, significantly exceeding the 20-41% rates observed for cyclosporine and methotrexate during comparable periods. "The aim of this literature review is to describ
- FDA Greenlights BIMZELX for Chronic Hidradenitis Suppurativahttps://practicaldermatology.com/news/fda-greenlights-bimzelx-chronic-hidradenitis-suppurativa/2468635/The Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for adults with moderate-to-severe hidradenitis suppurativa (HS), making it the first treatment to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). According to a press release f
- Acne Insights: Strategies and Solutions at 2024 SDPA Fallhttps://practicaldermatology.com/news/acne-insights-strategies-and-solutions-2024-sdpa-fall/2468634/The SDPA’s 22nd Annual Fall Dermatology Conference was held last week at the Fontainebleau in Las Vegas. Conference Medical Director Hilary Baldwin, MD, joined Shanna Miranti, MPAS, PA-C, in a discussion called “Acne Insights: Expert Strategies and Solutions from the Pros.” The presentatio